Posted by Michael Wonder on 31 Aug 2020
FDA approves Xaracoll (bupivacaine hydrochloride) implant, a non-opioid, drug-device treatment option for acute post-surgical pain relief for up to 24 hours following open inguinal hernia repair in adults
31 August 2020 - Xaracoll is a first-of-its-kind, fully bioresorbable collagen implant that delivers bupivacaine hydrochloride directly to the surgical site providing long-lasting pain relief.
Innocoll Holdings Limited announced today that the US FDA has approved Xaracoll for acute post-surgical pain relief for up to 24 hours in adults following open inguinal hernia repair, a painful and commonly-performed surgery.
